Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

(2012) A. Sexauer et al.   BLOOD

Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation

(2012) C. H. Man et al.   BLOOD

Ontogeny and Sorafenib Metabolism

(2012) E. I. Zimmerman et al.   CLINICAL CANCER RESEARCH

5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

(2012) N Curik et al.   LEUKEMIA

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

(2011) T. Sato et al.   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia

(2011) Aref Al-Kali et al.   Clinical Lymphoma Myeloma & Leukemia

FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype

(2011) K. Wagner et al.   HAEMATOLOGICA

p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia

(2011) K P Ng et al.   LEUKEMIA

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

(2011) S Negrotto et al.   LEUKEMIA

A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study

(2011) P Chevallier et al.   LEUKEMIA

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

(2010) S. Kurosawa et al.   HAEMATOLOGICA

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

(2010) K W Pratz et al.   LEUKEMIA

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

(2009) S. Metzelder et al.   BLOOD

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

(2009) J. Zhou et al.   BLOOD

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

(2009) Farhad Ravandi et al.   LEUKEMIA RESEARCH

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway

(2008) W Zhang et al.   LEUKEMIA